|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
09.03.26 - 12:01
|
enGene Reports First Quarter 2026 Financial Results and Provides Business Update (Business Wire)
|
|
|
LEGEND pivotal cohort update planned for a spring 2026 medical conference
12-month complete response data from LEGEND pivotal cohort expected in 2H 2026
Biologics License Application (BLA) submission for detalimogene planned for 2H 2026
Cash and marketable securities of $312.5 million expected to provide cash runway into 2H 2028
Expanded $125 million debt facility with Hercules Capital provides additional financial flexibility to advance detalimogene development and commercialization for bladder cancerBOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the first quarter ended January 31, 2026, and provided a business update.
“As data from LEGEND's pivotal cohort in high-risk, BCG-unresponsive NMIBC continues to mature, we look forward to providing an update at a spring medical conference,” said Ron Cooper, President and Chief Executive Officer, enGen...
|
|
|
|